Dyne Therapeutics (DYN) Cash from Financing Activities (2020 - 2026)

Dyne Therapeutics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $7.1 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 95.0% year-over-year to $7.1 million; the TTM figure through Mar 2026 stood at $756.1 million (up 39.32% YoY), while the FY2025 annual figure was $890.3 million, up 9.93% from the prior year.
• Cash from Financing Activities was $7.1 million for Q1 2026 at Dyne Therapeutics, down from $431.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $431.0 million in Q4 2025 to a low of $18000.0 in Q1 2022.
• Historically, Cash from Financing Activities has averaged $105.8 million across 5 years, with a median of $24.9 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities slumped 99.99% in 2022, then soared 159983.33% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at $37.2 million in 2022, then plunged by 99.6% to $147000.0 in 2023, then soared by 2373.47% to $3.6 million in 2024, then soared by 11752.72% to $431.0 million in 2025, then tumbled by 98.36% to $7.1 million in 2026.
• The last three Cash from Financing Activities figures came in at $7.1 million (Q1 2026), $431.0 million (Q4 2025), and $217.3 million (Q3 2025), per Business Quant data.